UF team plays major role in success of newly approved Duchenne muscular dystrophy drug
The drug is associated with slower functional decline and decreased fat replacement in muscle.
The drug is associated with slower functional decline and decreased fat replacement in muscle.
The grant supports continued efforts to develop MRI biomarkers for individuals with Duchenne muscular dystrophy, and expand the study to include people with Becker muscular dystrophy.
After treatment, three young boys with Duchenne muscular dystrophy had considerably lower fat infiltration in their muscles than boys receiving standard treatment.
PHHP researchers are working to give patients with muscular dystrophy longer, fuller lives.
Roxanna Bendixen, Ph.D., OTR/L, examines how disease and disability affect children’s participation in activities, social development and quality of life.